NCT05773053已完成2 期
A Prospective, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 Doses in the Treatment of Platysma Prominence
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 73
- 试验地点
- 7
- 主要终点
- Change From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Investigator at Visit 4 (V4)
研究概览
简要总结
The purpose of this study is to assess the safety and efficacy of NT 201 in adults with moderate to severe platysma prominence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of four (medial and lateral, left and right) prominent platysmal bands
- •Moderate to severe platysmal bands as assessed by the investigator and subject on the MAPS-D at maximum contraction
排除标准
- •Any serious disease or disorder (medical or psychiatric) that could interfere with the safe completion of treatment or compromise subject safety
- •Botulinum toxin treatment in the face (below the lower orbital rim), neck, or chest within the last 12 months prior to study treatment
- •History of lower face surgery, neck or chest surgery, aesthetic procedures (e.g., ablative skin resurfacing, laser, chemical peel, micro-focused ultrasound, deoxycholic acid injections, micro-needling, non-surgical fat reduction procedure), and orthodontic procedures (e.g., braces) in the 12 months prior to study treatment
- •Previous use of any permanent (non-biodegradable) or semi-permanent (e.g., calcium hydroxylapatite, poly-L-lactic acid, polymethyl methacrylate, etc.) facial tissue augmentation therapy, lifting sutures, permanent implants or autologous fat to the lower face (i.e., below the level of the bottom of the nose), neck, or chest within 24 months prior to study treatment
- •Previous use of any hyaluronic acid based or collagen based biodegradable facial tissue augmentation therapy to the lower face (i.e., below the level of the bottom of the nose), neck, or chest within 12 months prior to study treatment
- •Any medical condition that may put the subject at increased risk with exposure to botulinum toxin of any serotype, including myasthenia gravis, Lambert-Eaton-Syndrome, amyotrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function
- •Female of childbearing potential not using a highly effective method of birth control, planning to get pregnant, or pregnant or lactating
研究组 & 干预措施
NT 201 Dose 1
Experimental
Subjects will receive Dose 1.
干预措施: NT 201 (Drug)
NT 201 Dose 2
Experimental
Subjects will receive Dose 2.
干预措施: NT 201 (Drug)
NT 201 Dose 3
Experimental
Subjects will receive Dose 3.
干预措施: NT 201 (Drug)
Placebo
Placebo Comparator
Subjects will receive matching placebo.
干预措施: NT 201 Placebo (Drug)
结局指标
主要结局
Change From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Investigator at Visit 4 (V4)
时间窗: Baseline (Screening Visit), Week 2 (V4)
The platysma area will be assessed live by the investigator at maximum contraction and graded according to the validated five-point Merz Aesthetic Platysma Scale-Dynamic (MAPS-D). Scores range from Grade 1 (none to minimal) to Grade 5 (very severe).
次要结局
- Number of Subjects With Related Treatment Emergent Adverse Events (Related TEAEs)(Baseline up to Week 17/End of Study)
- Change From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Subject at V4(Baseline (Screening Visit), Week 2 (V4))
研究者
研究点 (7)
Loading locations...
相似试验
已完成
3 期
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual DisabilityChronic Troublesome SialorrheaTraumatic Brain InjuryStrokeCerebral PalsyIntellectual DisabilityNCT02270736Merz Pharmaceuticals GmbH256
已完成
1 期
A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the FaceEnlarged PoresSebum ProductionNCT05784363Merz North America, Inc.31
已完成
2 期
A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the ArmEssential Tremor of the Upper LimbNCT04766723Merz Pharmaceuticals GmbH78
已完成
3 期
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial LinesModerate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)NCT04622254Merz North America, Inc.368
已完成
3 期
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial LinesModerate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)NCT04594213Merz North America, Inc.362